{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:50:09Z","timestamp":1787165409599,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Many patients with metastatic and recurrent colorectal cancer (CRC) have poor outcomes, due to resistance to current treatment approaches. Missense mutations in the\n                    <jats:italic>TP53<\/jats:italic>\n                    gene are found in about 65% of CRCs, but no current treatment approach targets mutant\n                    <jats:italic>TP53<\/jats:italic>\n                    activity. To develop a vaccine approach against CRCs expressing a mutant p53 protein, we used a murine CRC model with conditional expression of a\n                    <jats:italic>Trp53<\/jats:italic>\n                    codon R270H missense allele, and immunized mice with the experimental vaccine, which combined a synthetic R270H p53 peptide and wild-type p53 recombinant protein with a mucosal nanoemulsion (NE) adjuvant. The p53\/NE vaccine was administered intranasally to the mice after mutant p53 induction and tumor initiation. Vaccinated mice had markedly increased serum anti-p53 IgG, IgG2a, and IgG2b as compared to control mice. The vaccination also enhanced antigen-specific Th1 and Th17 cellular immune responses, as shown by increasing production of IFN\u03b3, IL-17a and IL-2. The immunized animals had significantly decreased tumor size, prolonged survival and increased tumor CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell infiltrates. Collectively, we have demonstrated a mucosal vaccine against mutated p53 protein in CRC can induce antigen-specific cellular and humoral immunity. The findings suggest potential value in pursuing mutated p53 as a vaccine target in CRC.\n                  <\/jats:p>","DOI":"10.1038\/s41417-026-01035-6","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T13:07:19Z","timestamp":1777122439000},"page":"838-846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A p53 peptide mucosal vaccine induces cellular and humoral immunity and anti-tumor effects in a murine colorectal cancer model"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3317-9206","authenticated-orcid":false,"given":"Su He","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna W.","family":"Janczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maranne","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengzhuang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Fearon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James R.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"1035_CR1","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/cancers16081551","volume":"16","author":"A Patel","year":"2024","unstructured":"Patel A, Gulhati P. Molecular landscape and therapeutic strategies against colorectal cancer. Cancers. 2024;16:1551. https:\/\/doi.org\/10.3390\/cancers16081551.","journal-title":"Cancers"},{"key":"1035_CR2","doi-asserted-by":"publisher","unstructured":"Jia W, Shen X, Guo Z, Cheng X, Zhao R. The future of cancer vaccines against colorectal cancer. Expert Opin Biol Ther. 2024;1\u201316. https:\/\/doi.org\/10.1080\/14712598.2024.2341744.","DOI":"10.1080\/14712598.2024.2341744"},{"key":"1035_CR3","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3748\/wjg.v30.i13.1815","volume":"30","author":"S Sharma","year":"2024","unstructured":"Sharma S, Singh N, Turk AA, Wan I, Guttikonda A, Dong JL, et al. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: unravelling challenges and future directions. World J Gastroenterol. 2024;30:1815\u201335. https:\/\/doi.org\/10.3748\/wjg.v30.i13.1815.","journal-title":"World J Gastroenterol"},{"key":"1035_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104342","volume":"197","author":"A Marques","year":"2024","unstructured":"Marques A, Cavaco P, Torre C, Sepodes B, Rocha J. Tumor mutational burden in colorectal cancer: Implications for treatment. Crit Rev Oncol Hematol. 2024;197:104342. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104342.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1035_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ijc.33793","volume":"150","author":"KT Lynch","year":"2022","unstructured":"Lynch KT, Squeo GC, Kane WJ, Meneveau MO, Petroni G, Olson WC, et al. A pilot trial of vaccination with Carcinoembryonic antigen and Her2\/neu peptides in advanced colorectal cancer. Int J Cancer. 2022;150:164\u201373. https:\/\/doi.org\/10.1002\/ijc.33793.","journal-title":"Int J Cancer"},{"key":"1035_CR6","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.7150\/jca.70385","volume":"13","author":"S Kim","year":"2022","unstructured":"Kim S, Kim BJ, Kim I, Kim JH, Kim HK, Ryu H, et al. A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer. J Cancer. 2022;13:1363\u20139. https:\/\/doi.org\/10.7150\/jca.70385.","journal-title":"J Cancer"},{"key":"1035_CR7","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1158\/1078-0432.CCR-22-3168","volume":"29","author":"RE Schoen","year":"2023","unstructured":"Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenberg D, Hur C, et al. Randomized, double-blind, placebo-controlled trial of MUC1 peptide vaccine for prevention of recurrent colorectal adenoma. Clin Cancer Res. 2023;29:1678\u201388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3168.","journal-title":"Clin Cancer Res"},{"key":"1035_CR8","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00262-022-03307-0","volume":"72","author":"R Shi","year":"2023","unstructured":"Shi R, Zhou X, Pang L, Wang M, Li Y, Chen C, et al. Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer. Cancer Immunol Immunother. 2023;72:985\u20131001. https:\/\/doi.org\/10.1007\/s00262-022-03307-0.","journal-title":"Cancer Immunol Immunother"},{"key":"1035_CR9","doi-asserted-by":"publisher","unstructured":"Ahcene Djaballah S, Daniel F, Milani A, Ricagno G, Lonardi S. HER2 in colorectal cancer: the long and winding road from negative predictive factor to positive actionable target. Am Soc Clin Oncol Educ Book. 2022. https:\/\/doi.org\/10.1200\/EDBK_351354.","DOI":"10.1200\/EDBK_351354"},{"key":"1035_CR10","unstructured":"Kankanala VL, Mukkamalla SKR. Carcinoembryonic antigen. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK578172\/"},{"key":"1035_CR11","doi-asserted-by":"publisher","unstructured":"Kasprzak A, Siod\u0142a E, Andrzejewska M, Szmeja J, Seraszek-Jaros A, Cofta S, et al. Differential expression of mucin 1 and mucin 2 in colorectal cancer. World J Gastroenterol. 2018;24:4164\u201377. https:\/\/doi.org\/10.3748\/wjg.v24.i36.4164].","DOI":"10.3748\/wjg.v24.i36.4164"},{"key":"1035_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1987505","volume":"2016","author":"M Tarnowski","year":"2016","unstructured":"Tarnowski M, Czerewaty M, Deskur A, Safranow K, Marlicz W, Urasi\u0144ska E, et al. Expression of cancer testis antigens in colorectal cancer: new prognostic and therapeutic implications. Dis Markers. 2016;2016:1987505. https:\/\/doi.org\/10.1155\/2016\/1987505.","journal-title":"Dis Markers"},{"key":"1035_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2368288","volume":"20","author":"SC Park","year":"2024","unstructured":"Park SC, Wiest MJ, Yan V, Wong PT, Schotsaert M. Induction of protective immune responses at respiratory mucosal sites. Hum Vaccin Immunother. 2024;20:2368288. https:\/\/doi.org\/10.1080\/21645515.2024.2368288.","journal-title":"Hum Vaccin Immunother"},{"key":"1035_CR14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/v14030520","volume":"14","author":"F Feng","year":"2022","unstructured":"Feng F, Wen Z, Chen J, Yuan Y, Wang C, Sun C. Strategies to develop a mucosa-targeting vaccine against emerging infectious diseases. Viruses. 2022;14:520. https:\/\/doi.org\/10.3390\/v14030520.","journal-title":"Viruses"},{"key":"1035_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.imlet.2019.10.013","volume":"217","author":"M Li","year":"2020","unstructured":"Li M, Wang Y, Sun Y, Cui H, Zhu SJ, Qiu HJ. Mucosal vaccines: strategies and challenges. Immunol Lett. 2020;217:116\u201325. https:\/\/doi.org\/10.1016\/j.imlet.2019.10.013.","journal-title":"Immunol Lett"},{"key":"1035_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10039-y","volume":"22","author":"KM Kim","year":"2022","unstructured":"Kim KM, Ahn AR, Park HS, Jang KY, Moon WS, Kang MJ, et al. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer. BMC Cancer. 2022;22:940. https:\/\/doi.org\/10.1186\/s12885-022-10039-y.","journal-title":"BMC Cancer"},{"key":"1035_CR17","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3390\/cancers13092125","volume":"13","author":"MC Liebl","year":"2021","unstructured":"Liebl MC, Hofmann TG. The role of p53 signaling in colorectal cancer. Cancers. 2021;13:2125. https:\/\/doi.org\/10.3390\/cancers13092125.","journal-title":"Cancers"},{"key":"1035_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1021\/mp4005029","volume":"11","author":"PT Wong","year":"2014","unstructured":"Wong PT, Wang SH, Ciotti S, Makidon PE, Smith DM, Fan Y, et al. Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity. Mol Pharm. 2014;11:531\u201344.","journal-title":"Mol Pharm"},{"key":"1035_CR19","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1038\/s41374-019-0269-y","volume":"99","author":"J Tang","year":"2019","unstructured":"Tang J, Feng Y, Kuick R, Green M, Green M, Sakamoto N, et al. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis. Lab Invest. 2019;99:1454\u201369. https:\/\/doi.org\/10.1038\/s41374-019-0269-y.","journal-title":"Lab Invest"},{"key":"1035_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2022.100353","volume":"2","author":"JK Kim","year":"2022","unstructured":"Kim JK, Wu C, Del Latto M, Gao Y, Choi SH, Kierstead M, et al. An immunocompetent rectal cancer model to study radiation therapy. Cell Rep Methods. 2022;2:100353. https:\/\/doi.org\/10.1016\/j.crmeth.2022.100353.","journal-title":"Cell Rep Methods"},{"key":"1035_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s42826-021-00096-y","volume":"37","author":"H Arnesen","year":"2021","unstructured":"Arnesen H, M\u00fcller MHB, Aleksandersen M, \u00d8stby GC, Carlsen H, Paulsen JE, et al. Induction of colorectal carcinogenesis in the C57BL\/6J and A\/J mouse strains with a reduced DSS dose in the AOM\/DSS model. Lab Anim Res. 2021;37:19. https:\/\/doi.org\/10.1186\/s42826-021-00096-y.","journal-title":"Lab Anim Res"},{"key":"1035_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/02841860903334411","volume":"49","author":"K Derwinger","year":"2010","unstructured":"Derwinger K, Kodeda K, Bexe-Lindskog E, Taflin H. Tumour differentiation grade is associated with TNM staging and the risk of node metastasis in colorectal cancer. Acta Oncol. 2010;49:57\u201362. https:\/\/doi.org\/10.3109\/02841860903334411.","journal-title":"Acta Oncol"},{"key":"1035_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s42003-025-08251-0","volume":"8","author":"IY Luk","year":"2025","unstructured":"Luk IY, Mooi JK, Mouradov D, Tan T, Scott CM, Chionh F, et al. Model systems and unique biological features of high and low-grade colorectal cancer (CRC) revealed by xenografting 84 human CRC cell lines. Commun Biol. 2025;8:875. https:\/\/doi.org\/10.1038\/s42003-025-08251-0.","journal-title":"Commun Biol"},{"key":"1035_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41417-023-00717-9","volume":"31","author":"SH Wang","year":"2024","unstructured":"Wang SH, Cao Z, Farazuddin M, Chen J, Janczak KW, Tang S, et al. A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation. Cancer Gene Ther. 2024;31:464\u201371. https:\/\/doi.org\/10.1038\/s41417-023-00717-9.","journal-title":"Cancer Gene Ther"},{"key":"1035_CR25","doi-asserted-by":"publisher","first-page":"45951","DOI":"10.18632\/oncotarget.17504","volume":"8","author":"Y Tian","year":"2017","unstructured":"Tian Y, Li M, Yu C, Zhang R, Zhang X, Huang R, et al. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo. Oncotarget. 2017;8:45951\u201364. https:\/\/doi.org\/10.18632\/oncotarget.17504.","journal-title":"Oncotarget"},{"key":"1035_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1055\/s-0043-1761474","volume":"37","author":"D deLahunta","year":"2023","unstructured":"deLahunta D, Nalamati S. Management of surgically accessible lymph nodes beyond normal resection planes. Clin Colon Rectal Surg. 2023;37:71\u201379. https:\/\/doi.org\/10.1055\/s-0043-1761474.","journal-title":"Clin Colon Rectal Surg"},{"key":"1035_CR27","doi-asserted-by":"publisher","unstructured":"Ghirardello M, Guerreiro A, Bret\u00f3n C, Compa\u00f1\u00f3n I, Zabalza J, Mangini V, et al. Balancing antigen loading on gold nanoparticles: implications for future cancer vaccine strategies. Chemistry. 2025:e202501286. https:\/\/doi.org\/10.1002\/chem.202501286.","DOI":"10.1002\/chem.202501286"},{"key":"1035_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/CJI.0000000000000405","volume":"45","author":"S Nishida","year":"2022","unstructured":"Nishida S, Morimoto S, Oji Y, Morita S, Shirakata T, Enomoto T, et al. Cellular and humoral immune responses induced by an HLA class I-restricted peptide cancer vaccine targeting WT1 are associated with favorable clinical outcomes in advanced ovarian cancer. J Immunother. 2022;45:56\u201366. https:\/\/doi.org\/10.1097\/CJI.0000000000000405.","journal-title":"J Immunother"},{"key":"1035_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-26225-8","volume":"12","author":"AR Markowski","year":"2022","unstructured":"Markowski AR, Markowska AJ, Ustymowicz W, Pryczynicz A, Guzi\u0144ska-Ustymowicz K. Simultaneous analysis of tumor-infiltrating immune cells density, tumor budding status, and presence of lymphoid follicles in CRC tissue. Sci Rep. 2022;12:21732. https:\/\/doi.org\/10.1038\/s41598-022-26225-8.","journal-title":"Sci Rep"},{"key":"1035_CR30","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3389\/fimmu.2020.01052","volume":"11","author":"L Guo","year":"2020","unstructured":"Guo L, Wang C, Qiu X, Pu X, Chang P. Colorectal cancer immune infiltrates: significance in patient prognosis and immunotherapeutic efficacy. Front Immunol. 2020;11:1052. https:\/\/doi.org\/10.3389\/fimmu.2020.01052.","journal-title":"Front Immunol"},{"key":"1035_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00262-018-2287-9","volume":"68","author":"AA Chiappori","year":"2019","unstructured":"Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, et al. Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. Cancer Immunol Immunother. 2019;68:517\u201327. https:\/\/doi.org\/10.1007\/s00262-018-2287-9.","journal-title":"Cancer Immunol Immunother"},{"key":"1035_CR32","doi-asserted-by":"publisher","first-page":"e1500671","DOI":"10.1080\/2162402X.2018.1500671","volume":"7","author":"J Quandt","year":"2018","unstructured":"Quandt J, Schlude C, Bartoschek M, Will R, Cid-Arregui A, Sch\u00f6lch S, et al. Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. Oncoimmunology. 2018;7:e1500671. https:\/\/doi.org\/10.1080\/2162402X.2018.1500671.","journal-title":"Oncoimmunology"},{"key":"1035_CR33","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/ijc.27819","volume":"132","author":"EC Zeestraten","year":"2013","unstructured":"Zeestraten EC, Speetjens FM, Welters MJ, Saadatmand S, Stynenbosch LF, Jongen R, et al. Addition of interferon-\u03b1 to the p53-SLP\u00ae vaccine results in increased production of interferon-\u03b3 in vaccinated colorectal cancer patients: a phase I\/II clinical trial. Int J Cancer. 2013;132:1581\u201391. https:\/\/doi.org\/10.1002\/ijc.27819.","journal-title":"Int J Cancer"},{"key":"1035_CR34","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-08-2227","volume":"15","author":"FM Speetjens","year":"2009","unstructured":"Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res. 2009;15:1086\u201395. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2227.","journal-title":"Clin Cancer Res"},{"key":"1035_CR35","first-page":"1019","volume":"8","author":"SH van der Burg","year":"2002","unstructured":"van der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfhout JW, Tollenaar RA, et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res. 2002;8:1019\u201327.","journal-title":"Clin Cancer Res"},{"key":"1035_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115976","volume":"170","author":"Q Shang","year":"2024","unstructured":"Shang Q, Yu X, Sun Q, Li H, Sun C, Liu L. Polysaccharides regulate Th1\/Th2 balance: A new strategy for tumor immunotherapy. Biomed Pharmacother. 2024;170:115976. https:\/\/doi.org\/10.1016\/j.biopha.2023.115976.","journal-title":"Biomed Pharmacother"},{"key":"1035_CR37","doi-asserted-by":"publisher","first-page":"11673","DOI":"10.3390\/ijms241411673","volume":"24","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, Wieder T, Mauerer B, Sch\u00e4fer L, Kesselring R, Braum\u00fcller H. T cells in colorectal cancer: unravelling the function of different T cell subsets in the tumor microenvironment. Int J Mol Sci. 2023;24:11673. https:\/\/doi.org\/10.3390\/ijms241411673.","journal-title":"Int J Mol Sci"},{"key":"1035_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.123927","volume":"237","author":"Y Qu","year":"2023","unstructured":"Qu Y, Yang H, Li S, Li L, Li Y, Wang D. The involvement of Th1 cell differentiation in the anti-tumor effect of purified polysaccharide from Sanghuangporus vaninii in colorectal cancer via multi-omics analysis. Int J Biol Macromol. 2023;237:123927. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.123927.","journal-title":"Int J Biol Macromol"},{"key":"1035_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1154836","volume":"14","author":"X Luo","year":"2023","unstructured":"Luo X, Song Z, Zeng X, Ye Y, Zheng H, Cai D, et al. A promising self-nanoemulsifying adjuvant with plant-derived saponin D boosts immune response and exerts an anti-tumor effect. Front Immunol. 2023;14:1154836. https:\/\/doi.org\/10.3389\/fimmu.2023.1154836.","journal-title":"Front Immunol"},{"key":"1035_CR40","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2127691","volume":"11","author":"L Guo","year":"2022","unstructured":"Guo L, Overholser J, Darby H, Ede NJ, Kaumaya PTP. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). Oncoimmunology. 2022;11:2127691. https:\/\/doi.org\/10.1080\/2162402X.2022.2127691.","journal-title":"Oncoimmunology"},{"key":"1035_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2261326","volume":"12","author":"C Rodriguez","year":"2023","unstructured":"Rodriguez C, Araujo Furlan CL, Tosello Boari J, Bossio SN, Boccardo S, Fozzatti L, et al. Interleukin-17 signaling influences CD8+ T cell immunity and tumor progression according to the IL-17 receptor subunit expression pattern in cancer cells. Oncoimmunology. 2023;12:2261326. https:\/\/doi.org\/10.1080\/2162402X.2023.2261326.","journal-title":"Oncoimmunology"},{"key":"1035_CR42","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e6","volume":"20","author":"DS Kuen","year":"2020","unstructured":"Kuen DS, Kim BS, Chung Y. IL-17-producing cells in tumor immunity: friends or foes?. Immune Netw. 2020;20:e6. https:\/\/doi.org\/10.4110\/in.2020.20.e6.","journal-title":"Immune Netw"},{"key":"1035_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin O, Oren M. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov. 2023;22:127\u201344. https:\/\/doi.org\/10.1038\/s41573-022-00571-8.","journal-title":"Nat Rev Drug Discov"},{"key":"1035_CR44","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.3390\/molecules29225315","volume":"29","author":"Y Peng","year":"2024","unstructured":"Peng Y, Bai J, Li W, Su Z, Cheng X. Advancements in p53-based anti-tumor gene therapy research. Molecules. 2024;29:5315. https:\/\/doi.org\/10.3390\/molecules29225315.","journal-title":"Molecules"},{"key":"1035_CR45","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","volume":"23","author":"RJ Greenwald","year":"2005","unstructured":"Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515\u201348.","journal-title":"Annu Rev Immunol"},{"key":"1035_CR46","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1035_CR47","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371. https:\/\/doi.org\/10.1038\/nature13954.","journal-title":"Nature"},{"key":"1035_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1200\/JCO.22.02270","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2023;41:715\u201323. https:\/\/doi.org\/10.1200\/JCO.22.02270. Feb 1PMID: 36706735.","journal-title":"J Clin Oncol"},{"key":"1035_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42560-w","volume":"13","author":"J Li","year":"2023","unstructured":"Li J, Lv M, Huang Q, Hu R, Zhong X, Sun X, et al. FAT4 expression in peripheral blood mononuclear cells is associated with prognosis and immune cell infiltration in hepatocellular carcinoma. Sci Rep. 2023;13:15735. https:\/\/doi.org\/10.1038\/s41598-023-42560-w.","journal-title":"Sci Rep"},{"key":"1035_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978862","volume":"13","author":"ZA Bazzi","year":"2023","unstructured":"Bazzi ZA, Sneddon S, Zhang PGY, Tai IT. Characterization of the immune cell landscape in CRC: clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC. Front Immunol. 2023;13:978862. https:\/\/doi.org\/10.3389\/fimmu.2022.978862.","journal-title":"Front Immunol"},{"key":"1035_CR51","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12866-022-02712-w","volume":"22","author":"Z Qi","year":"2022","unstructured":"Qi Z, Zhibo Z, Jing Z, Zhanbo Q, Shugao H, Weili J, et al. Prediction model of poorly differentiated colorectal cancer (CRC) based on gut bacteria. BMC Microbiol. 2022;22:312. https:\/\/doi.org\/10.1186\/s12866-022-02712-w.","journal-title":"BMC Microbiol"},{"key":"1035_CR52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.bbrc.2021.02.001","volume":"546","author":"S Wang","year":"2021","unstructured":"Wang S, Fan X, Zhu J, Xu D, Li R, Chen R, et al. The differentiation of colorectal cancer is closely relevant to m6A modification. Biochem Biophys Res Commun. 2021;546:65\u201373. https:\/\/doi.org\/10.1016\/j.bbrc.2021.02.001.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01035-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01035-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01035-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:49:48Z","timestamp":1786448988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01035-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01035-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7652612\/v1","asserted-by":"object"}]},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}